Beyond corrective shoeing, the primary medical treatments for navicular syndrome are bisphosphonates (clodronate disodium or tiludronate), intra-synovial corticosteroid and hyaluronate injections, and extracorporeal shock wave therapy (ESWT), with emerging interest in orthobiologic approaches.
Clodronate disodium (Osphos) is the only FDA-approved bisphosphonate with a labeled dose for navicular syndrome in horses. A single dose of 1.4 mg/kg IM (maximum 900 mg/horse) achieves a treatment success rate of 74.7% at day 56 post-treatment, defined as ≥1 AAEP grade improvement in the primarily affected limb without worsening of the contralateral forelimb, compared to 3.3% in saline controls.FDA DailyMed An…
Tiludronate administered via intravenous regional limb perfusion (IVRLP) is an adjunctive bisphosphonate option. It has been evaluated as an adjunct to therapeutic shoeing and distal interphalangeal joint (DIPJ) injections.American Journa… Tiludronate administered by either systemic or IVRLP routes produced no adverse reactions related to colic or renal disease during a 7-day post-administration monitoring period.American Journa… Bisphosphonates are thought to slow excessive bone resorption, which is a central feature of navicular syndrome's progressive degenerative course.American Journa…
Intra-synovial corticosteroid and hyaluronate injection — targeting the navicular bursa, DIPJ, or digital flexor tendon sheath (DFTS) — is a mainstay of medical management. Corticosteroids have positive clinical effects in horses with osteoarthritic lameness for up to 70 days after intra-articular injection.American Journa… Triamcinolone acetonide diffuses readily from the DIPJ into the adjacent navicular bursa in horses, supporting DIPJ injection as a route to treat both structures simultaneously.American Journa… Methylprednisolone acetate (100 mg) combined with sodium hyaluronate (20 mg) injected into the DFTS is used when deep digital flexor tendon (DDFT) injury extends proximally beyond the navicular bursa.Journal of the…
Navicular bursa injection outcomes are strongly influenced by the specific MRI-defined pathology present. Of 101 horses treated with navicular bursa corticosteroid and hyaluronate injection, 75% returned to intended use for a mean of 9.62 months (median 5 months, range 0–48 months), and 35% remained sound at follow-up.Journal of the… Horses with navicular bursitis characterized by excessive fluid on MRI had the best outcomes, while those with scar tissue in the proximal navicular bursa had a poor outcome.Journal of the… Lameness duration under 6 months, navicular bursa injection, and DFTS injection were all significantly correlated with return to intended use for a longer period.Journal of the… Horses with primary DDFT lesions and navicular bursitis respond better to navicular bursa corticosteroid injections than horses with concurrent navicular bone fibrocartilage, cartilage surface, or collateral ligament pathologies.American Journa…
ESWT using a focused (not radial) generator, targeting the lesion site through the heel bulbs and sole, produces good therapeutic effects for navicular syndrome. Radial ESWT has been shown to be ineffective — one protocol using a radial machine at 4 bar pressure, 10 Hz frequency, with 1,500 pulses applied between the heel bulbs and 1,500 pulses over the middle third of the frog failed to improve lameness.Frontiers in Ve… Focused ESWT that comprehensively targets the lesion site is the recommended approach.Frontiers in Ve…
Orthobiologic therapies, including mesenchymal stem cell (MSC)-derived extracellular vesicles, are an emerging area of investigation. Equine bone marrow MSC-derived extracellular vesicles have demonstrated mitigation of interleukin-1β-driven inflammation in navicular tissues in vitro, with potential anti-inflammatory, immunomodulatory, and trophic effects.Equine Veterina… Clinical application remains investigational.
| Treatment | Dose / Protocol | Efficacy | Key Caveat |
|---|---|---|---|
| Clodronate disodium (Osphos) | 1.4 mg/kg IM, single dose (max 900 mg) | 74.7% treatment success at day 56 | Approved only for bony navicular changes; soft tissue/fracture/OA cases excluded from label indication FDA DailyMed An… |
| Tiludronate (IVRLP) | Adjunct to shoeing and DIPJ injection | Objective lameness improvement; no adverse reactions observed | Not evaluated as monotherapy in this protocol American Journa…+1 |
| Navicular bursa ± DFTS injection (MPA + hyaluronate) | 100 mg MPA + 20 mg sodium hyaluronate per synovial space | 75% return to use; mean 9.62 months soundness | Poor outcome with proximal bursal scar tissue; MPA may upregulate MMP-13 in navicular bone fibrocartilage cells under inflammatory conditions Journal of the…+1 |
| Focused ESWT | Focused generator targeting heel bulbs and sole | Good therapeutic effects reported | Radial ESWT (4 bar, 10 Hz, 3,000 total pulses) failed to improve lameness Frontiers in Ve… |
| MSC-derived extracellular vesicles | In vitro only | Mitigates IL-1β inflammation in navicular tissues | No clinical outcome data yet Equine Veterina… |
Would you like guidance on how to sequence these treatments — for example, when to escalate from bisphosphonates and shoeing to intra-synovial injection or ESWT?